IonQ has gained 67% in a month and 13% this week alone — yet options traders are adding downside protection at their most defensive posture in months, even as short sellers continue to retreat.
The short cover story has moved further since Wednesday's note. Short interest has dropped to 20.3% of the free float, down from the 23–24% range that held for six weeks through mid-May. That is roughly 13 million shares returned over the past month. The borrow market confirms the unwind: availability has risen to 12.3% from a near-total freeze of just 0.14% on May 22 — a level so extreme that fewer than one share remained available for every 700 already borrowed. The pool is no longer in crisis, though at 12% it remains tight by any historical standard. Critically, cost to borrow has stayed subdued at 1.23%, actually edging lower on the week. That combination — covering short sellers, easing availability, no spike in borrow costs — points to position reduction rather than a fresh wave of bearish conviction.
Options tell a different story. The put/call ratio has climbed to 1.11, more than two standard deviations above its 20-day mean of 1.04. That is the most defensive options positioning of the past year, outside the 52-week high of 1.42. While shorts are retreating, options traders are paying more for downside protection on a stock that has already more than doubled from its April lows. The two signals point in opposite directions: short sellers exiting, options buyers hedging. The net read is a market that believes in the rally enough to close losing shorts, but not enough to stop buying puts.
The Street is cautiously constructive but well behind the price. The consensus is a hold, with just two formal ratings on record. The most recent moves — JP Morgan raised its target to $50 from $42 in early May, while Wedbush lifted to $75 — both still trail the current $72 price, with only Rosenblatt's $100 target sitting materially above. That leaves the mean target at $67.64, actually below where the stock closed Friday. EPS momentum ranks in the 85th percentile on a 30-day basis, reflecting the sharp upward revision following the May earnings beat. Revenue growth topped 300% year-on-year. Yet the stock trades at a deeply negative P/E and an EV/EBITDA that remains in the red — classical pre-profitability quantum territory where sentiment and milestone delivery drive the multiple rather than traditional valuation.
The institutional picture shows some incremental buying at the margins. Morgan Stanley Investment Management added roughly 959,000 shares through April, and Goldman Sachs added 1.68 million shares through March. UBS Asset Management added 1.6 million over the same period. These are not large positions relative to total float, but the direction is consistent: larger allocators are building, not cutting. On the insider side, the pattern is the opposite — the Executive Chairman and CFO both sold in early May at prices well below the current level, a reminder that management was trimming into strength that turned out to be the start of a much larger move.
With the next earnings event confirmed for June 16, the positioning setup heading into that print is worth watching: the put/call ratio at a two-standard-deviation extreme, short interest still elevated at a fifth of the float, and the borrow pool only partially refilled after weeks of near-total exhaustion. The question at that report — whether a company growing revenue at triple-digit rates can narrow its losses fast enough to support a stock now priced near $72 — is the same one the Street's divided analyst targets have yet to resolve.
See the live data behind this article on ORTEX.
Open IONQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
